YESTERDAY'S UPDATE
Here's the hot news from Adaptive Biotechnologies $ADPT (-0,05Â %) (NASDAQ: ADPT) Q2 2026 earnings release, fresh off the US market close:
🚀 Top-line Performance & MRD Booster
Adaptive Biotechnologies $ADPT is gaining significant momentum in its core diagnostics business in the second quarter of 2026. The primary growth driver remains the Minimal Residual Disease (MRD) division, centered around the flagship clonoSEQ test:
clonoSEQ volume: Test volume surged by +43% year-over-year to 36,111 tests. Adoption for blood cancer analyses continues to grow rapidly in medical practices and clinics.
Immune Medicine segment: Revenue in this segment fell nominally by -40% to $5.4 million. Adjusted for the expired Genentech agreement, however, the business grew organically by +8%.
đź”® Significant Jumps in Profitability
While the net loss still stood at $39.9 million, operating leverage is having a massive impact on the core diagnostics business:
Adjusted EBITDA for the entire company improved dramatically from a loss of -$7.2 million in the prior-year period to nearly break-even (-$0.7 million).
The MRD segment alone generated an adjusted EBITDA of $9.1 million (compared to $1.9 million in the same quarter of the previous year). The diagnostics division is thus already generating solid operating profits.
🤖 Forecast Upgrade & Financial Statement Adjustment
Forecast Upgrade: Thanks to the strong growth driver clonoSEQ, management is raising the MRD annual revenue forecast to $268 million to $278 million (previously $260 million–$270 million). This corresponds to an implied annual growth rate of 26% to 31%.
Financial Flexibility: With $371.7 million in cash and marketable securities, the balance sheet is rock-solid, supported by a recently successfully placed convertible bond. In addition, the planned spin-off or strategic separation of the two divisions (MRD vs. Immune Medicine) has been further advanced.
⚡ 💡 Jack’s Conclusion
The transformation into a profitable commercial diagnostics specialist is taking on increasingly concrete form! Thanks to clonoSEQ (+43% in volume), the “disposable biotech” image is a thing of the past, and the core MRD segment is already generating solid revenue. The fact that the annual forecast has been raised once again provides the bulls with compelling arguments.